| Literature DB >> 32610687 |
Nansi López-Valverde1, Javier Flores-Fraile1, Juan Manuel Ramírez2, Bruno Macedo de Sousa3, Silvia Herrero-Hernández1, Antonio López-Valverde1.
Abstract
Animal studies and the scarce clinical trials available that have been conducted suggest that bioactive surfaces on dental implants could improve the osseointegration of such implants. The purpose of this systematic review was to compare the effectiveness of osseointegration of titanium (Ti) dental implants using bioactive surfaces with that of Ti implants using conventional surfaces such as sandblasted large-grit acid-etched (SLA) or similar surfaces. Applying the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, the MEDLINE, PubMed Central and Web of Science databases were searched for scientific articles in April 2020. The keywords used were "dental implants", "bioactive surfaces", "biofunctionalized surfaces", and "osseointegration", according to the question: "Do bioactive dental implant surfaces have greater osseointegration capacity compared with conventional implant surfaces?" Risk of bias was assessed using the Cochrane Collaboration tool. 128 studies were identified, of which only 30 met the inclusion criteria: 3 clinical trials and 27 animal studies. The average STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) and ARRIVE (Animal Research: Reporting of In Vivo Experiments) scores were 15.13 ± 2.08 and 17.7±1.4, respectively. Implant stability quotient (ISQ) was reported in 3 studies; removal torque test (RTT)-in 1 study; intraoral periapical X-ray and microcomputed tomography radiological evaluation (RE)-in 4 studies; shear force (SF)-in 1 study; bone-to-implant contact (BIC)-in 12 studies; and BIC and bone area (BA) jointly-in 5 studies. All animal studies reported better bone-to-implant contact surface for bioactive surfaces as compared to control implants with a statistical significance of p < 0.05. Regarding the bioactive surfaces investigated, the best results were yielded by the one where mechanical and chemical treatment methods of the Ti surfaces were combined. Hydroxyapatite (HA) and calcium-phosphate (Ca-Ph) were the most frequently used bioactive surfaces. According to the results of this systematic review, certain bioactive surfaces have a positive effect on osseointegration, although certain coating biomolecules seem to influence early peri-implant bone formation. Further and more in-depth research in this field is required to reduce the time needed for osseointegration of dental implants.Entities:
Keywords: Ti dental implants; bioactive surfaces; biofunctionalized surfaces; osseointegration
Year: 2020 PMID: 32610687 PMCID: PMC7408888 DOI: 10.3390/jcm9072047
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Publications in the US National Library of Medicine database with the following keywords: “bioactive surfaces” and “dental implants.” Source: US National Library of Medicine [18].
Checklist of the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) criteria reported in the human studies.
| Studies | Gursoytrak, B., Ataoglu, H. 2020 [ | Malchiodi et al. 2011 [ | Mistry et al. 2010 [ |
|---|---|---|---|
| Section and item | |||
| 1. Title and abstract | 1 | 1 | 1 |
| Introduction | |||
| 2.Background | 1 | 1 | 1 |
| 3. Objectives | 1 | 1 | 1 |
| Methods | |||
| 4. Study design | 1 | 1 | 1 |
| 5. Setting | 1 | 1 | 1 |
| 6. Participants | 1 | 1 | 1 |
| 7. Variables | 1 | 0 | 1 |
| 8. Data sources/measurement | 1 | 1 | 1 |
| 9. Bias | 0 | 0 | 0 |
| 10. Study size | 1 | 1 | 1 |
| 11.Quantitative variables | 1 | 1 | 1 |
| 12. Statistical methods | 1 | 0 | 1 |
| Results | |||
| 13. Participants | 1 | 1 | 1 |
| 14. Descriptive data | 0 | 0 | 0 |
| 15. Outcome data | 1 | 1 | 1 |
| 16. Main results | 1 | 1 | 1 |
| 17. Other analyses | 0 | 0 | 1 |
| Discussion | |||
| 18. Key results | 1 | 1 | 1 |
| 19. Limitations | 0 | 0 | 0 |
| 20. Interpretation | 0 | 0 | 0 |
| 21. Generalizability | 0 | 0 | 0 |
| Other information | |||
| 22. Funding | 1 | 0 | 1 |
| Total score | 16 | 13 | 17 |
Mode Value: 15.13 ± 2.08. Each item was attributed a score of “0” (not reported) or “1” (reported). The total score of each of the included studies was also recorded.
Checklist of the ARRIVE (Animal Research: Reporting of In Vivo Experiments) criteria reported in the included studies.
| Studies | Cho et al. 2019 [ | Łukas Zewska-Kuska et al. 2019 [ | Romero-Ruiz et al. 2019 [ | Lee et al. 2019 [ | Thiem et al. 2019 [ | Chan et al. 2018 [ | Romero-Gavilan et al. 2018 [ | Huanhuan et al. 2017 [ | Herrero-Climent et al.2018 [ | Su et al. 2017 [ | van Oirschot et al. 2014 [ | Galli et al. 2014 [ | Kang et al. 2013 [ | Gobbato et al. 2012 [ | Choi et al. 2012 [ | Aparicio et al. 2011 [ | Diefenbeck et al. 2011 [ | Azen ha et al. 2010 [ | Lutz et al. 2010 [ | Quaranta et al. 2010 [ | Barros et al. 2009 [ | Granato et al. 2011 [ | Fawzy et al. 2008 [ | Faeda et al. 2009 [ | Alexander et al. 2009 [ | Germanier et al. 2006 [ | Teixeira et al. 2012 [ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Abstract | |||||||||||||||||||||||||||
| 2. Species | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3. Key finding | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Introduction | |||||||||||||||||||||||||||
| 4. Background | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 5. Reasons for animal models | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 6. Objectives | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Methods | |||||||||||||||||||||||||||
| 7. Ethical statement | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| 8. Study design | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 9. Experimental procedures | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 10. Experimental animals | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 11. Accommodation and handling of animals | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 12. Sample size | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 13. Assignment of animals to experimental groups | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| 14. Anesthesia | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 15. Statistical methods | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Results | |||||||||||||||||||||||||||
| 16. Experimental results | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 17. Results and estimation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Discussion | |||||||||||||||||||||||||||
| 18. Interpretation and scientific implications | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 19. 3Rs reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 20. Adverse events | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 21. Study limitations | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 22.Generalization/applicability | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 23. Funding | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Total Score | 20 | 20 | 20 | 17 | 20 | 19 | 18 | 19 | 16 | 16 | 16 | 16 | 16 | 16 | 18 | 19 | 17 | 17 | 18 | 19 | 16 | 17 | 17 | 17 | 19 | 18 | 17 |
Mode Value: 17.7 ± 1.4. Each item was attributed a score of “0” (not reported) or “1” (reported). The total score of each of the included studies was also recorded.
Figure 2Flowchart.
Animal studies.
| Studies | Animals | Surface Preparation | Number of Implants | Implantation Sites | Tracing (Weeks) | Conclusions | BIC Values | BA Values | ISQ Values | RTT Values | RE Values | SF Values | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test | Control | Test | Control | Test | Control | Test | Control | Test | Control | Test | Control | |||||||
| New Zealand white rabbit model | A human vitronectin-derived peptide, VnP-16 | 16 | Tibia | 2 weeks | VnP-16 reinforces the osteogenic potential of an SLA titanium dental implant when this peptide is applied to the SLA surface. | NR | NR | NR | NR | NR | NR | NR |
| NR | NR | |||
| New Zealand white rabbit model | Hydroxyapatite (HA) coating | 20 | Tibia | 2 weeks | The HA coating reported herein was found to have chemical and physical properties which appear to improve osseointegration compared to grit-blasted implants. | NR | NR | NR | 69.85 | NR | NR | NR | NR | NR | NR | NR | NR | |
| Minipig model | ContacTi® (alumina particle bombardment of titanium bioactivated when treated thermochemically) | 12 | Jaw, premolar and molar area. | 8 weeks | The surface ContacTi® showed remarkable results in terms of the osseointegration process. | NR | NR | NR | 73.5 | NR | NR | NR | NR | NR | NR | NR | NR | |
| Dog model | (IS-III Bioactive®) SLA with HA nanocoating | 9 | Jaw, the second, the third, and the fourth premolars area | 4 weeks | Osteoblasts might become more activated with the use of an HA-coated surface. | 77.28 ± 11.22% | 68.80 ± 10.67% | 44.94 ± 17.69% | 36.53 ± 13.72% | NR | NR | NR | NR | NR | NR | |||
| New Zealand white rabbit model | Nanocrystalline SiO2–HA coating | 36 | Femur | 2 and 4 weeks | Distance osteogenesis does not seem to become affected by a bioactive SiO2–HA surface coating. | 2 weeks, 66 ± 3% ** 4 weeks **, 65 ± 2% | 2 weeks, 42 ± 1% 4 weeks, 44 ± 1% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | Bioactive glass fiber-reinforced composite (GFRC) | 12 | Femur | 8 weeks | Histological evaluation revealed more newly formed bone regeneration in the GFRC implant group during the initial healing period. | 37.9 ± 1.6% ** | 37.1 ± 5.9% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | Silica hybrid sol-gel coating applied onto the Ti substrate (35M35G30T) | 10 | Tibia | 4 weeks | Implants coated with the 35M35G30T coating demonstrated a clear increase in inflammatory activity, surely due to an associated, natural, and controlled immune response. | NR | NR | NR | NR | NR | NR | NR | NR | 40.4 ± 27.9% *** | 44.4 ± 21.6% | NR | NR | |
| Rat model | Sr overcoated acid-etched titanium implant (SLA) | 20 | Tibia | 2 and 8 weeks | The Sr–SLA surface showed increased BIC (Bone of Implant Contact) and new bone apposition around the implants. The result indicated that the Sr–SLA surface has an effect that improves early osseointegration. | 2 weeks **, 28.76 ± 8.44% 8 weeks **, 62.5 ± 35.78% | 2 weeks, 22.57 ± 6.29% 8 weeks, 45.54 ± 9.59% | 2 weeks, 12.02 ± 4.45% 8 weeks, 41.62 ± 7.75% | 2 weeks, 9.82 ± 3.49 8 weeks, 29.55 ± 5.53% | NR | NR | NR | NR | NR | NR | NR | NR | |
| Minipig model | Blasting of combined abrasive Al2O3 particles with thermochemical treatment (ContacTi®) | 20 | Maxillae | 2, 4, and 8 weeks | The ContacTi® surface achieved faster growth of hard tissues around the implants compared to the blasting surface, and for all the histomorphometric parameters evaluated, the values were higher. | 2 weeks, 49.02 ± 26.3% 4 weeks **, 83.20 ± 8.12% 8 weeks **, 85.58 ± 3.81% | 2 weeks, 39.32 ± 2.48% 4 weeks, 46.53 ± 9.81% 8 weeks, 46.20 ± 3.54% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Rat model | Ca nanosurface | 24 | Femur | 8 weeks | Nanostructure modification with incorporation of Ca2+ ions has a synergistic effect on the bone response to the implant. | NR | NR | NR | NR | NR | NR | NR | NR | 20.58 ± 3.02% ** | 70.25 ± 4.53% | NR | NR | |
| Goat model | HA coating | 20 | Iliac crest | 4 weeks | HA coating enhanced the biological properties compared to grit-blasted/acid-etched implants. | 57.5 ± 8.5% ** | 40.7 ± 13.2% | 43.6 ± 9.0% **** | 32.0 ± 10.4% | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | Coated with thin films of mesoporous TiO2 having pore diameters of 6 nm and loaded with magnesium | 20 | Tibia | 3 weeks | Local release of magnesium from implant surfaces improves implant retention in the early healing stage (3 weeks after implantation). | 15.2 ± 17.6% **** | 8.51 ± 3.4% | 66.61 ± 10.3% **** | 74.4 ± 15.2% | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | Laminin-2-derived peptide | 12 | Tibia | Not reported | Titanium implants coated with a laminin-2-derived peptide can promote osseointegration by accelerating new bone formation in vivo. | ‡‡ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | Ca–Ph-coated (BAE-2) | 16 | Tibia | 1, 3, and 13 weeks | The bioactive BAE-2 implant surface provided healthy bone remodeling at 21 days of healing. | ‡‡ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | Bioactive fluoride-modified | 10 | Tibia | 2 weeks | The surface modified with bioactive fluoride does not show superiority in the early bone response. | 42.6 ± 4.0% **** | 36.0 ± 5.4% | 47.0 ± 5.4% **** | 47.4 ± 3.4% | NR | ||||||||
| Minipig model | Micro-rough acid-etched (2Step) | 32 | Mandible and maxilla | 2, 4, 6, and 10 weeks | The 2Step treatment produced micro-rough and bioactive implants that accelerated bone tissue regeneration and increased mechanical retention in the bone bed at short periods of implantation. | ‡ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Rat model | Plasma chemical oxidation (Ca–Ph) (TiOB surface) | 128 | Tibia | 3 and 8 weeks | The bioactive TiOB surface has a positive effect on implant anchorage by enhancing the bone–implant contact. | NR | NR | 3 weeks, 47.4 ± 11.5% ** 8 weeks, 60.8 ± 7.8% ** | 3 weeks, 27.5 ± 4.40% 8 weeks, 69.0 ± 6.04% | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | SiO2–P2O5–Na2O, CaO, and Bioglass®45S5 | 64 | Femur | 8 and 12 weeks | All tested materials are biocompatible and are suitable to be used in clinical dentistry. | 8 weeks, 93 ± 6.55% **** 12 weeks, 90 ± 9% **** | 8 weeks, 87 ± 8% 12 weeks, 92 ± 8% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Pig model | The experimental implants were coated with HA and additionally with an active biomimetic peptide (P-15) | 12 | Jaw, premolar and molar area. | 2 and 4 weeks | Biofunctionalization of the implant surface with a biomimetic active peptide leads to significantly increased BIC rates at 14 and 30 days and higher peri-implant bone density at 30 days. | 2 weeks, 76.7 ± 26.1% 4 weeks, 75.8 ± 23.9% | 2 weeks, 63.8 ± 28.1% 4 weeks, 75.8 ± 23.9% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | Plasma-sprayed calcium-phosphate (PSCa–Ph) | 48 | Femur | 2, 4, and 8 weeks | Bioactive ceramic coatings were biocompatible and osteoconductive. However, the early bone response was favored by the presence of the thicker PSCaP coating. | 3 weeks, 27.1 ± 1.1% 4 weeks, 43.0 ± 3.0% 8 weeks, 61.0 ± 4.5% ** | 3 weeks, 23.0 ± 0.2% 4 weeks, 31.5 ± 2.4% 8 weeks, 46.0 ± 4.1% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Dog model | Application of a thin HA + bioactive peptide coating | 32 | Mandibular premolar area | 8 weeks | Biofunctionalization of the implant surface interferes with bone apposition around titanium implants, especially in terms of bone density. | 47.0 ± 16.8% **** | 41.4 ± 18.7% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Dog model | Bioactive ceramic coating deposition on an alumina-blasted/acid-etched surface | 16 | Tibia | 2 and 4 weeks | A thin bioactive ceramic coating on the implant surface did not affect BIC, but positively affected the biomechanical fixation of the implant. | 2 weeks, 71.70 ± 20.37% 4 weeks, 75.70 ± 18.20% **** | 2 weeks, 79.02 ± 16.02% 4 weeks, 86.99 ± 8.40% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| New Zealand white rabbit model | NaOH/heat treatment | 46 | Tibia | 2, 4, and 8 weeks | The sodium removal treatment was shown to be effective in improving the early resistance of the bone–implant interface. | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 2 weeks, 91.12 ± 36.57% 4 weeks, 240.72 ± 97.41% 8 weeks, 562.45 ± 132.93% ** | 2 weeks, 61.50 ± 28.15% 4 weeks, 214.56 ± 61.31% 8 weeks, 508.20 ± 111.78% | |
| New Zealand white rabbit model | HA coatings | 96 | Tibia | 4, 8, and 12 weeks | Implants with the HA biomimetic coating can shorten the healing period of implants by increasing the implant–bone interaction during the first 2 months after implant placement. | NR | NR | NR | NR | NR | NR | NR | NR | 2 weeks, 55.42 ± 12.86% 8 weeks, 24.0 ± 6.34% 12 weeks, 33.85 ± 6.28% ** | 2 weeks, 23.28 ± 4.46% 8 weeks, 63.71 ± 14.79% 12 weeks, 64.0 ± 18.05% | NR | NR | |
| Non-human primate model | Ca–Ph surface | 25 | Lower jaw | 30 weeks | Implant coating with ultra-fine calcium phosphate favors osteoconductive properties in the early phase with the avoidance of adverse reactions against the material during the later stages of osseointegration. | 74.9 ± 9.8% **** | 73.2 ± 17% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Miniature pig model | Arg–Gly–Asp (RGD) peptide-modified polymer (PLL-g-PEG/PEG–RGD) (poly(L lysine)- | 48 | Anterior maxilla | 2 and 4 weeks | Significant enhancement of new bone apposition to the RGD-functionalized SLA surface during the very early stages. | 2 weeks, 61.68 ± 4.21% *** 4 weeks, 62.52 ± 8.04% *** | 2 weeks, 43.62 ± 10.79% 4 weeks, 62.46 ± 6.37% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| Dog model | Alumina-blasted and acid-etched (AB/AE) surface | 36 | Center of the radius diaphysis | 2 and 4 weeks | Dental implant treatment with textured surfaces with argon plasma produced substantial improvements in biomechanical fixation in the early stages of implantation. | 2 weeks ‡ | 2 weeks ‡ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
HA (hydroxyapatite); SIO2 (silicon dioxide); Sr (strontium); SLA (sandblasted with long-grit corundum followed by acid etching with sulfuric and hydrochloric acid); Al2O3 (aluminum oxide); Ca (calcium); Ta (tantalum); P (phosphorus); P2O5 (Phosphorus Oxide); CaO (Calcium Oxide); NaOH (Sodium Hydroxide). BIC (bone implant contact); BA (bone area); ISQ (implant stability quotient); RTT (removal torque test); RE (radiological evaluation); SF (shear force); NR, not reported; ‡ Reported in a figure; ‡‡ Reported in a histological image. Significance: * p < 0.01, ** p < 0.05, *** p < 0.001, **** p > 0.01.
Human studies.
| Studies | Type of Study | Surface Preparation | Number of Implants | Implantation Sites | Tracing (Weeks) | Conclusions | BIC Values | ISQ Values | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Test | Control | Test | Control | |||||||
| Gursoytrak, B., Ataoglu, H. 2020 [ | Randomized clinical study | Alkali-modified (bioactive) and sandblasted surfaces | 50 (2 groups) | Mandibular molar area | 2, 6, and 12 weeks | No significant differences. The ISQ of the bioactive implants that exhibit high primary stability fell more than those of the implants with sandblasted surfaces at 2 and 6 weeks after the operation; both types of implants produced similar clinical results at 12 weeks post-operation. | NR | NR | 2 weeks, 73.68 ± 3.84% 6 weeks, 69.8 ± 4.61% 12 weeks, 73.40 ± 4.30% * | 2 weeks, 72.91 ± 4.63%6 weeks, 71.36 ± 7.42 12 weeks, 72.15 ± 3.39% |
| Malchiodi et al. 2011 [ | Case series | Resorbable calcium phosphate (CaP) coating made of brushite (FBR) | 3 | Posterior mandible | 8, 10, and 12 weeks | Immediately loaded FBR implants placed in the posterior jaw can achieve osseointegration within 6–12 weeks of loading. | 54.4 ± 3.74% **** | 70.1 ± 2.16% | NR | NR |
| Mistry et al. 2010 [ | Not reported | Bioactive glass (BG) coating | 62 | Anterior maxilla and anterior mandible | 12 months | Overall results showed that BG-coated implants are as successful as HA-coated implants in achieving osseointegration. | Bioactive glass group: 6 months, 0.93 ± 0.26% 12 months, 0.78 ± 0.42% | HA group: 6 months, 0.92 ± 0.30% 12 months, 0.82 ± 0.40% ** | NR | NR |
BIC (bone implant contact); ISQ (implant stability quotient); NR, not reported. Significance: * p < 0.01, ** p < 0.05, **** p > 0.01.
Figure 3Risk of bias in clinical studies.
Figure 4Risk of bias in animal studies.